Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.69 |
| ▸ | CCNK | O75909 | 2/20 | 0.60 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.60 |
| ▸ | CDK2 | P24941 | 2/20 | 0.60 |
| ▸ | CCND3 | P30281 | 2/20 | 0.60 |
| ▸ | CDK9 | P50750 | 2/20 | 0.60 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.60 |
| ▸ | BRD4 | O60885 | 13/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29793817 | 1.00 | EGFR (0.69) | EGFRCCNKCCNA2CDK2CCND3 | |
| Hydrochloric Acid SCHEMBL264814 | 0.99 | EGFR (0.68) | EGFRCCNKCCNA2CDK2CCND3 | |
| SCHEMBL269204 | 0.86 | EGFR (0.65) | EGFRCCNKCCNA2CDK2CCND3 | |
| Hydrochloric Acid SCHEMBL264469 | 0.85 | EGFR (0.64) | EGFRCCNKCCNA2CDK2CCND3 | |
| SCHEMBL263148 | 0.84 | EGFR (0.62) | EGFRCCNKCCNA2CDK2CCND3 | |
| SCHEMBL270128 | 0.83 | CCNK (0.71) | CCNKCCNA2CDK2CCND3CDK9 | |
| Hydrochloric Acid SCHEMBL264699 | 0.82 | CCNK (0.70) | CCNKCCNA2CDK2CCND3CDK9 | |
| SCHEMBL24625518 | 0.82 | EGFR (1.00) | EGFRBRD4 | |
| SCHEMBL14390071 | 0.81 | EGFR (0.59) | EGFRCCNKCCNA2CDK2CCND3 | |
| SCHEMBL764487 | 0.81 | CCNK (0.59) | EGFRCCNKCCNA2CDK2CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858914-B2 | Pyrimidine small-molecule compound and application thereof | WENZHOU MEDICAL UNIVERSITY (CN) | 2024-01-02 | — | — | US | disclosed |
| US-11858914-B2 | Pyrimidine small-molecule compound and application thereof | WENZHOU MEDICAL UNIVERSITY (CN) | 2024-01-02 | — | — | US | disclosed |
| US-20230312529-A1 | PYRIMIDINE SMALL-MOLECULE COMPOUND AND APPLICATION THEREOF | WENZHOU MEDICAL UNIVERSITY (CN) | 2023-10-05 | — | — | US | disclosed |
| US-20230312529-A1 | PYRIMIDINE SMALL-MOLECULE COMPOUND AND APPLICATION THEREOF | WENZHOU MEDICAL UNIVERSITY (CN) | 2023-10-05 | — | — | US | disclosed |
| WO-2022148243-A1 | PYRIMIDINE SMALL-MOLECULE COMPOUND AND APPLICATION THEREOF | 温州医科大学 | 2022-07-14 | — | — | WO | disclosed |
| EP-1951684-B1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN INC (US) | 2016-07-13 | — | — | EP | disclosed |
| US-8138199-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138199-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8133900-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8133900-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | TARGEGEN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | IMPACT BIOMEDICINES, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | IMPACT BIOMEDICINES, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7528143-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-7528143-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| WO-2007053452-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312529-A1 | PYRIMIDINE SMALL-MOLECULE COMPOUND AND APPLICATION THEREOF | PDGFRB, PDGFRA, RB1 | EGFR 966/4885CCNK 116/4885CCNA2 687/4885 |
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, LTK | EGFR 335/4885CCNK 405/4885CCNA2 1274/4885 |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | EGFR 181/4885CCNK 189/4885CCNA2 836/4885 |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | EGFR 181/4885CCNK 189/4885CCNA2 836/4885 |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, JAK3 | EGFR 181/4885CCNK 189/4885CCNA2 836/4885 |
| US-11858914-B2 | Pyrimidine small-molecule compound and application thereof | PDGFRB, PDGFRA, RB1 | EGFR 966/4885CCNK 116/4885CCNA2 687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.